Thulium Fiber Laser vs. Holmium:YAG Laser for the Ureteroscopic Treatment of Patients With Urinary Stone Disease
Launched by IRCCS SAN RAFFAELE · Mar 5, 2024
Trial Information
Current as of May 25, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is comparing two types of lasers used in a procedure called flexible ureteroscopy to treat kidney and ureteral stones. One laser is called Thulium fiber laser (TFL), and the other is the holmium:yttrium-aluminum-garnet (Ho:YAG) laser. The goal of the study is to see if TFL is more effective and safer than Ho:YAG for breaking down stones that are larger than 4 mm in size.
To be eligible for this trial, participants should be between the ages of 65 and 159 and have kidney or ureteral stones that are larger than 4 mm. If you have any anatomical abnormalities in your urinary system, you may not qualify. Those who participate can expect to undergo a procedure where one of the lasers will be used to treat their stones. The trial is currently recruiting participants, and it aims to gather information that could help improve treatment options for people with urinary stone disease.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Renal/ureteral stones \> 4 mm
- Exclusion Criteria:
- • Anatomical abnormalities
About Irccs San Raffaele
IRCCS San Raffaele is a prestigious research hospital and clinical trial sponsor based in Milan, Italy, renowned for its commitment to advancing medical science through innovative research and high-quality patient care. As an Institute for Research and Healthcare, it specializes in a wide range of therapeutic areas, including oncology, neurology, and cardiology, and is dedicated to translating scientific discoveries into effective clinical practices. With a multidisciplinary team of experts and state-of-the-art facilities, IRCCS San Raffaele plays a pivotal role in conducting rigorous clinical trials that contribute to the development of novel treatments and improve patient outcomes globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milan, Mi, Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported